300199 翰宇药业
交易中 03-12 10:05:51
资讯
新帖
简况
政旦志远会计所2025年收入破亿
YCY会计行业观察 · 02-28
政旦志远会计所2025年收入破亿
翰宇药业：公司已通过前瞻性布局产能扩张、持续完善质量体系与全球合规认证
证券之星 · 02-27
翰宇药业：公司已通过前瞻性布局产能扩张、持续完善质量体系与全球合规认证
翰宇药业（300199）披露召开2026年第二次临时股东会的通知，2月25日股价上涨2.63%
证券之星 · 02-25
翰宇药业（300199）披露召开2026年第二次临时股东会的通知，2月25日股价上涨2.63%
翰宇药业：预计2025年归母净利润扭亏为盈
证券之星 · 02-25
翰宇药业：预计2025年归母净利润扭亏为盈
翰宇药业（300199）披露醋酸格拉替雷注射液获美国FDA批准证书，2月24日股价下跌0.44%
证券之星 · 02-24
翰宇药业（300199）披露醋酸格拉替雷注射液获美国FDA批准证书，2月24日股价下跌0.44%
翰宇药业(300199.SZ)：醋酸格拉替雷注射液获得美国FDA批准证书
智通财经 · 02-12
翰宇药业(300199.SZ)：醋酸格拉替雷注射液获得美国FDA批准证书
翰宇药业最新公告：2025年预盈4000万元–5000万元GLP-1制剂与原料药业务规模大幅放量
证券之星 · 01-28
翰宇药业最新公告：2025年预盈4000万元–5000万元GLP-1制剂与原料药业务规模大幅放量
中国药企拿下诺和诺德订单？涉1.8亿元GLP-1原料药
健识局 · 01-19
中国药企拿下诺和诺德订单？涉1.8亿元GLP-1原料药
翰宇药业（300199）公司公告披露股东会决议，1月16日股价上涨0.97%
证券之星 · 01-16
翰宇药业（300199）公司公告披露股东会决议，1月16日股价上涨0.97%
翰宇药业最新公告：签订1.8亿元GLP-1原料药销售订单订单金额占2024年经审计营业收入的30.50%
证券之星 · 01-15
翰宇药业最新公告：签订1.8亿元GLP-1原料药销售订单订单金额占2024年经审计营业收入的30.50%
股市必读：翰宇药业（300199）12月29日董秘有最新回复
证券之星 · 2025-12-30
股市必读：翰宇药业（300199）12月29日董秘有最新回复
翰宇药业：司美格鲁肽减重适应症随访工作12月底可全部完成
证券之星 · 2025-12-29
翰宇药业：司美格鲁肽减重适应症随访工作12月底可全部完成
翰宇药业：海南昊天健康科技有限公司已无关联关系
证券之星 · 2025-12-25
翰宇药业：海南昊天健康科技有限公司已无关联关系
翰宇药业战略参股碳云智肽
新京报 · 2025-12-22
翰宇药业战略参股碳云智肽
翰宇药业（300199）披露控股股东、实际控制人办理部分股票质押暨股票解除质押业务，12月18日股价下跌0.56%
证券之星 · 2025-12-18
翰宇药业（300199）披露控股股东、实际控制人办理部分股票质押暨股票解除质押业务，12月18日股价下跌0.56%
翰宇药业：国际业务保持良好增长势头
证券之星 · 2025-12-16
翰宇药业：国际业务保持良好增长势头
翰宇药业（300199）披露控股股东、实际控制人办理部分股票解除质押暨办理股票质押业务，12月11日股价下跌0.79%
证券之星 · 2025-12-11
翰宇药业（300199）披露控股股东、实际控制人办理部分股票解除质押暨办理股票质押业务，12月11日股价下跌0.79%
翰宇药业（300199）公司公告补选非独立董事及修订公司章程，12月08日股价上涨1.59%
证券之星 · 2025-12-08
翰宇药业（300199）公司公告补选非独立董事及修订公司章程，12月08日股价上涨1.59%
翰宇药业：多肽原料药总产能可达5吨以上
证券之星 · 2025-12-03
翰宇药业：多肽原料药总产能可达5吨以上
医药“一哥”高管，空降翰宇药业
蓝鲸财经 · 2025-11-28
医药“一哥”高管，空降翰宇药业
公司概况
公司名称：
深圳翰宇药业股份有限公司
所属行业：
医药制造业
上市日期：
2011-04-07
主营业务：
深圳翰宇药业股份有限公司的主营业务是多肽药物研发、生产和销售。公司的主要产品是多肽制剂、多肽原料药、小核酸、CDMO/CMO。公司共获得国内专利授权298件，其中发明专利291件；翰宇药业（武汉）获得国内专利授权18件；成纪药业共获得国内专利授权115件。
发行价格：
30.19
{"stockData":{"symbol":"300199","market":"SZ","secType":"STK","nameCN":"翰宇药业","latestPrice":17.69,"timestamp":1773281151000,"preClose":18.07,"halted":0,"volume":8071500,"delay":0,"changeRate":-0.021,"floatShares":746000000,"shares":883000000,"eps":-0.0765,"marketStatus":"交易中","change":-0.38,"latestTime":"03-12 10:05:51","open":18.07,"high":18.07,"low":17.6,"amount":144000000,"amplitude":0.026,"askPrice":17.69,"askSize":34,"bidPrice":17.68,"bidSize":14,"shortable":0,"etf":0,"ttmEps":-0.0765,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1773286200000},"marketStatusCode":2,"adr":0,"adjPreClose":18.07,"symbolType":"stock","openAndCloseTimeList":[[1773279000000,1773286200000],[1773291600000,1773298800000]],"highLimit":19.88,"lowLimit":16.26,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":883241336,"isCdr":false,"pbRate":24.59,"roa":"--","roe":"11.62%","epsLYR":-0.2,"committee":0.002362,"marketValue":15625000000,"turnoverRate":0.0108,"status":1,"floatMarketCap":13191000000},"requestUrl":"/m/hq/s/300199/wiki","defaultTab":"wiki","newsList":[{"id":"2614661008","title":"政旦志远会计所2025年收入破亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2614661008","media":"YCY会计行业观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614661008?lang=zh_cn&edition=full","pubTime":"2026-02-28 00:02","pubTimestamp":1772208120,"startTime":"0","endTime":"0","summary":"最近一个会计年度的收入总额12,123.23万元，审计业务收入为10,599.28万元，证券业务收入为8,421.43万元。2025年度上市公司年报审计收费：4,967万元。截止公告日，政旦志远（深圳）会计师事务所已购买职业责任保险，职业保险累计赔偿限额：10,000万元，并计提职业风险基金。部分会计所2025年业务收入：","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-02-28/doc-inhphuva0535406.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0070","BK0239","BK0188","BK0077","300199"],"gpt_icon":0},{"id":"2614088226","title":"翰宇药业：公司已通过前瞻性布局产能扩张、持续完善质量体系与全球合规认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2614088226","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614088226?lang=zh_cn&edition=full","pubTime":"2026-02-27 15:48","pubTimestamp":1772178487,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业(300199)02月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司跟礼来有直接或间接业务往来吗？翰宇药业回复：尊敬的投资者您好！公司业务合作情况请以公告和公众号等官方信息为准。目前全球 GLP‑1 原料药市场正处于高速增长阶段，随着口服剂型的普及、减重适应症的不断拓展，行业整体市场规模预计将持续快速扩容。公司已通过前瞻性布局产能扩张、持续完善质量体系与全球合规认证，为迎接市场扩容、巩固行业领先地位做好了充足准备。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700021723.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300199","BK0188","BK0239","BK0028","BK0077"],"gpt_icon":0},{"id":"2614380550","title":"翰宇药业（300199）披露召开2026年第二次临时股东会的通知，2月25日股价上涨2.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614380550","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614380550?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:12","pubTimestamp":1772028740,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘，翰宇药业报收于18.7元，较前一交易日上涨2.63%，最新总市值为165.17亿元。该股当日开盘18.23元，最高18.7元，最低18.17元，成交额达3.69亿元，换手率为2.67%。近日，翰宇药业发布《关于召开2026年第二次临时股东会的通知》。公告显示，公司将于2026年3月16日召开2026年第二次临时股东会，会议由公司董事会召集，采取现场投票与网络投票相结合的方式。股权登记日为2026年3月9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500037934.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","300199","BK0070","BK0028","BK0239","BK0077"],"gpt_icon":0},{"id":"2614082535","title":"翰宇药业：预计2025年归母净利润扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2614082535","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614082535?lang=zh_cn&edition=full","pubTime":"2026-02-25 20:52","pubTimestamp":1772023954,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业02月25日在投资者关系平台上答复投资者关心的问题。投资者提问：为何公司25年下半年业绩变化如此无常，利润如此低下呢？翰宇药业回复：尊敬的投资者您好，1 月 28 日，公司发布 2025 年度业绩预告，预计全年实现营业收入 9.50 亿元至 9.80 亿元，归母净利润实现扭亏为盈，达到 4000 万元至 5000 万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500036500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199"],"gpt_icon":0},{"id":"2613544791","title":"翰宇药业（300199）披露醋酸格拉替雷注射液获美国FDA批准证书，2月24日股价下跌0.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613544791","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613544791?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:32","pubTimestamp":1771925562,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，翰宇药业报收于18.22元，较前一交易日下跌0.44%，最新总市值为160.93亿元。该股当日开盘18.49元，最高18.49元，最低18.14元，成交额达2.28亿元，换手率为1.67%。近日，深圳翰宇药业股份有限公司收到美国食品药品监管局下发的醋酸格拉替雷注射液新药简略申请批准证书，ANDA号为213382、214022，规格为20mg/mL、40mg/mL。该药品用于治疗复发型多发性硬化，可降低复发频率，延缓疾病进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400033146.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","300199","BK0070","BK0028","BK0239","BK0077"],"gpt_icon":0},{"id":"2610577946","title":"翰宇药业(300199.SZ)：醋酸格拉替雷注射液获得美国FDA批准证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2610577946","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610577946?lang=zh_cn&edition=full","pubTime":"2026-02-12 17:19","pubTimestamp":1770887976,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)发布公告，近日，公司收到美国食品药品监管局(以下简称“FDA”)下发的醋酸格拉替雷注射液新药简略申请(以下简称“ANDA”)批准证书。醋酸格拉替雷是一种用于治疗复发型多发性硬化(MS)的免疫调节药物，属于合成多肽类制剂，通过模拟髓鞘碱性蛋白的结构，调节异常的自身免疫反应，从而减少对中枢神经系统髓鞘的攻击。该药可降低复发频率，延缓疾病进展，适用于临床孤立综合征及复发缓解型多发性硬化患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404701.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰宇药业(300199.SZ)：醋酸格拉替雷注射液获得美国FDA批准证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0239","BK0188","BK0070","BK0077","300199"],"gpt_icon":0},{"id":"2606797279","title":"翰宇药业最新公告：2025年预盈4000万元–5000万元GLP-1制剂与原料药业务规模大幅放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2606797279","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606797279?lang=zh_cn&edition=full","pubTime":"2026-01-28 18:39","pubTimestamp":1769596768,"startTime":"0","endTime":"0","summary":"翰宇药业(300199.SZ)公告称，翰宇药业预计2025年归属于上市公司股东的净利润为盈利4000万元–5000万元，上年同期为亏损17365.40万元。报告期内，公司预计归属于上市公司股东的净利润实现扭亏为盈。主要原因在于公司GLP-1制剂与原料药业务规模大幅放量，CRDMO业务落地推进。同时持续加大以创新药HY3003为首的研发投入力度，提高核心产品的竞争力。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800034921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","300199","BK0077","BK0239","BK0070"],"gpt_icon":0},{"id":"2604135410","title":"中国药企拿下诺和诺德订单？涉1.8亿元GLP-1原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2604135410","media":"健识局","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604135410?lang=zh_cn&edition=full","pubTime":"2026-01-19 20:28","pubTimestamp":1768825711,"startTime":"0","endTime":"0","summary":"1月16日，翰宇药业发布公告称：公司与一家客户签订了合同，涉及采购金额1.8亿元的GLP-1原料药。翰宇药业作为原料药市场的先行者，无疑是供应链转移的受益者。2023年9月，翰宇药业发布公告称，旗下子公司武汉翰宇与美国某客户签订累计金额3000万美元的GLP-1多肽原料药。翰宇药业借助向“美国客户”销售GLP-1原料药产品的优势，开始在行业里确立供应商的地位。这笔1.8医院的GLP-1原料订单，能否扭转翰宇药业持续亏损的颓势，目前还不好说。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119205354a43d0d23&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119205354a43d0d23&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","BK4590","BK4144","BK4588","BK4599","BK4532","IE00BKVL7J92.USD","LU0154236417.USD","LU1093756168.USD","300199","LU1093756325.SGD","NVO","BK4007","BK4585"],"gpt_icon":0},{"id":"2603087994","title":"翰宇药业（300199）公司公告披露股东会决议，1月16日股价上涨0.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603087994","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603087994?lang=zh_cn&edition=full","pubTime":"2026-01-16 22:50","pubTimestamp":1768575027,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，翰宇药业报收于20.9元，较前一交易日上涨0.97%，最新总市值为184.6亿元。该股当日开盘21.43元，最高21.75元，最低20.75元，成交额达10.68亿元，换手率为6.78%。近日，深圳翰宇药业股份有限公司召开2026年第一次临时股东会，会议由董事会召集，采用现场与网络投票相结合方式举行。出席会议股东共766人，代表股份占公司有表决权股份总数的22.0224%。表决结果显示两项议案均获高比例同意通过。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600041600.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0077","BK0188","BK0239","300199","BK0028"],"gpt_icon":0},{"id":"2603606987","title":"翰宇药业最新公告：签订1.8亿元GLP-1原料药销售订单订单金额占2024年经审计营业收入的30.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603606987","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603606987?lang=zh_cn&edition=full","pubTime":"2026-01-15 18:31","pubTimestamp":1768473078,"startTime":"0","endTime":"0","summary":"翰宇药业(300199.SZ)公告称，公司与某客户签订《销售订单》，其拟向公司合计采购金额为1.8亿元人民币的GLP-1原料药。该订单金额占2024年经审计营业收入的30.50%，若订单顺利履行，预计会对公司年度经营业绩产生积极影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500031358.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199"],"gpt_icon":0},{"id":"2595734448","title":"股市必读：翰宇药业（300199）12月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2595734448","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595734448?lang=zh_cn&edition=full","pubTime":"2025-12-30 01:19","pubTimestamp":1767028749,"startTime":"0","endTime":"0","summary":"截至2025年12月29日收盘，翰宇药业报收于18.59元，下跌0.75%，换手率2.64%，成交量19.69万手，成交额3.68亿元。公司司美格鲁肽减重适应症受试者已完成全部治疗访视，随访工作12月底可全部完成；司美格鲁肽降糖适应症受试者将于12月底完成治疗访视，随访工作将于 2026年1月全部结束。当日关注点来自交易信息汇总：12月29日主力资金净流出2748.44万元，散户资金净流入3006.47万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000000767.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","BK0188","BK0028","300199","BK0077"],"gpt_icon":0},{"id":"2595780953","title":"翰宇药业：司美格鲁肽减重适应症随访工作12月底可全部完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2595780953","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595780953?lang=zh_cn&edition=full","pubTime":"2025-12-29 20:51","pubTimestamp":1767012668,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业12月29日在投资者关系平台上答复投资者关心的问题。还有RWA还有没有后续，要给股民一个交代呀翰宇药业回复：尊敬的投资者您好！公司司美格鲁肽减重适应症受试者已完成全部治疗访视，随访工作12月底可全部完成；司美格鲁肽降糖适应症受试者将于12月底完成治疗访视，随访工作将于 2026年1月全部结束。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900034562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300199","BK0028","BK0188","BK0070","BK0239"],"gpt_icon":0},{"id":"2594033234","title":"翰宇药业：海南昊天健康科技有限公司已无关联关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2594033234","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594033234?lang=zh_cn&edition=full","pubTime":"2025-12-25 20:52","pubTimestamp":1766667133,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业(300199)12月24日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，董秘，请问贵公司子公司海南昊天健康科技有限公司，是否还在正常营业运作？是归属全资子公司吗？翰宇药业回复：尊敬的投资者您好，海南昊天健康科技有限公司原系公司全资子公司，后续基于业务布局优化调整已处置，现已与公司无关联关系。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500033407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","BK0077","BK0028","300199","BK0188"],"gpt_icon":0},{"id":"2593510716","title":"翰宇药业战略参股碳云智肽","url":"https://stock-news.laohu8.com/highlight/detail?id=2593510716","media":"新京报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593510716?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:08","pubTimestamp":1766390880,"startTime":"0","endTime":"0","summary":"新京报贝壳财经讯 12月22日，据翰宇药业微信公众号消息，近日翰宇药业与深圳碳云智肽药物科技有限公司（简称“碳云智肽”）正式达成战略投资合作。根据协议约定，翰宇药业将以1000万元现金认购碳云智肽新增注册资本，增资完成后持有其0.6623%股权，标志着双方从前期研发协作迈向资本绑定与产业协同的深度合作新阶段。","market":"sh","thumbnail":"https://media.bjnews.com.cn/cover/2025/12/22/5667201163137721813.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/cover/2025/12/22/5667201163137721813.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1766390338129383.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1766390338129383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["BK0239","BK0070","BK0028","300199","BK0077","BK0188"],"gpt_icon":0},{"id":"2592790106","title":"翰宇药业（300199）披露控股股东、实际控制人办理部分股票质押暨股票解除质押业务，12月18日股价下跌0.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592790106","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592790106?lang=zh_cn&edition=full","pubTime":"2025-12-18 22:07","pubTimestamp":1766066829,"startTime":"0","endTime":"0","summary":"截至2025年12月18日收盘，翰宇药业报收于17.91元，较前一交易日下跌0.56%，最新总市值为158.19亿元。该股当日开盘17.9元，最高18.44元，最低17.83元，成交额达3.04亿元，换手率为2.25%。公司近日发布公告称，控股股东、实际控制人曾少贵先生近日办理了部分股票质押及解除质押业务。同日，曾少贵先生解除质押股份19,000,000股，占其所持股份比例19.28%，占公司总股本比例2.15%。本次质押与解质后，曾少贵先生累计质押股份数量不变。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800037994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300199","BK0028","BK0188","BK0077","BK0070"],"gpt_icon":0},{"id":"2591130984","title":"翰宇药业：国际业务保持良好增长势头","url":"https://stock-news.laohu8.com/highlight/detail?id=2591130984","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591130984?lang=zh_cn&edition=full","pubTime":"2025-12-16 20:52","pubTimestamp":1765889538,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业(300199)12月16日在投资者关系平台上答复投资者关心的问题。投资者提问：股价喋喋不休！是什么情况？据说现在公司没有订单？是否属实翰宇药业回复：尊敬的投资者您好，2025年，公司的国际业务继续保持着良好的增长势头，海外市场业务正有序推进，我们与核心合作伙伴始终保持长期稳定的战略合作关系。公司严格按照相关法律法规履行信息披露义务，如签订达到披露标准的重大合同，公司将严格按照监管要求及时发布公告。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600038122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300199","BK0239","BK0188","BK0077","BK0070"],"gpt_icon":0},{"id":"2590851158","title":"翰宇药业（300199）披露控股股东、实际控制人办理部分股票解除质押暨办理股票质押业务，12月11日股价下跌0.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590851158","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590851158?lang=zh_cn&edition=full","pubTime":"2025-12-11 22:03","pubTimestamp":1765461836,"startTime":"0","endTime":"0","summary":"截至2025年12月11日收盘，翰宇药业报收于18.75元，较前一交易日下跌0.79%，最新总市值为165.61亿元。该股当日开盘19.1元，最高19.16元，最低18.75元，成交额达3.19亿元，换手率为2.26%。公司近日发布公告称，控股股东、实际控制人曾少贵、曾少彬近日办理了部分股票解除质押及新的股票质押业务。本次质押后，曾少贵累计质押47,190,000股，占其所持股份47.89%；曾少彬累计质押12,500,000股，占其所持股份57.56%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100041090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0077","BK0028","BK0188","300199","BK0239"],"gpt_icon":0},{"id":"2589133675","title":"翰宇药业（300199）公司公告补选非独立董事及修订公司章程，12月08日股价上涨1.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589133675","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589133675?lang=zh_cn&edition=full","pubTime":"2025-12-08 17:43","pubTimestamp":1765187000,"startTime":"0","endTime":"0","summary":"截至2025年12月8日收盘，翰宇药业报收于19.2元，较前一交易日上涨1.59%，最新总市值为169.58亿元。该股当日开盘19.02元，最高19.45元，最低19.01元，成交额达5.93亿元，换手率为4.14%。近日，深圳翰宇药业股份有限公司发布2025年第四次临时股东会决议公告，披露公司已于2025年12月5日召开2025年第四次临时股东大会，审议通过了补选第六届董事会非独立董事、修订公司章程、调整公司架构及办理工商变更登记、修订多项内部制度等议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800021730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300199","BK0188","BK0070","BK0077"],"gpt_icon":0},{"id":"2588915530","title":"翰宇药业：多肽原料药总产能可达5吨以上","url":"https://stock-news.laohu8.com/highlight/detail?id=2588915530","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588915530?lang=zh_cn&edition=full","pubTime":"2025-12-03 11:48","pubTimestamp":1764733699,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业(300199)12月02日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好，关于替尔泊肽原料药明年的预计产能是？谢谢翰宇药业回复：您好，目前公司多肽原料药总产能可达5吨以上，具体产品的年度排产计划将综合市场及合作需求等动态制定，感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300013704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","BK0028","BK0070","300199","BK0239"],"gpt_icon":0},{"id":"2586206136","title":"医药“一哥”高管，空降翰宇药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2586206136","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586206136?lang=zh_cn&edition=full","pubTime":"2025-11-28 14:45","pubTimestamp":1764312358,"startTime":"0","endTime":"0","summary":"事后，涉案原高管被判刑，公司计提相关费用，对利润产生显著冲击。一个偶然的契机，其发现国内多肽赛道有巨大成长空间，由此找到医药专家袁建成，共同组建翰宇药业的前身。2022年，袁建成挪用公司资金案彻底浮出水面，其本人于2024年被终审判刑。其中，司美格鲁肽因受技术保护期限，国产厂家仍未获批上市，但进度较快的华东医药早已摩拳擦掌等待专利“开闸”。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1764293051486213495","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0188","BK0028","BK1515","159938","BK0070","09939","BK0239","BK1574","BK0077","BK1161","300199"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1773281155381,"stockEarnings":[{"period":"1week","weight":0.1045},{"period":"1month","weight":-0.0352},{"period":"3month","weight":-0.0363},{"period":"6month","weight":-0.2818},{"period":"1year","weight":0.3954},{"period":"ytd","weight":0.0095}],"compareEarnings":[{"period":"1week","weight":0.0125},{"period":"1month","weight":0.0025},{"period":"3month","weight":0.0672},{"period":"6month","weight":0.0679},{"period":"1year","weight":0.223},{"period":"ytd","weight":0.0415}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳翰宇药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"110118人(较上一季度增加74.86%)","perCapita":"6771股","listingDate":"2011-04-07","address":"广东省深圳市龙华区观澜高新园区观盛四路7号翰宇创新产业大楼","registeredCapital":"88324万元","survey":" 深圳翰宇药业股份有限公司的主营业务是多肽药物研发、生产和销售。公司的主要产品是多肽制剂、多肽原料药、小核酸、CDMO/CMO。公司共获得国内专利授权298件，其中发明专利291件；翰宇药业（武汉）获得国内专利授权18件；成纪药业共获得国内专利授权115件。","listedPrice":30.19},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰宇药业,300199,翰宇药业股票,翰宇药业股票老虎,翰宇药业股票老虎国际,翰宇药业行情,翰宇药业股票行情,翰宇药业股价,翰宇药业股市,翰宇药业股票价格,翰宇药业股票交易,翰宇药业股票购买,翰宇药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}